Ricevi le ultime notizie sulle azioni Terns Pharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di TERN

Ultime notizie per

TERNS PHARMACEUTICALS INC

Terns Pharma

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Equities

News

Movers

TERN

Il nuovo farmaco TERN-601 mostra risultati promettenti nella perdita di peso in sole 4 settimane con dosi giornaliere.

Nuovo farmaco promette di far perdere peso in sole 4 settimane

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharmaceuticals Inc

TERN PLC by Tern PLC

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium SA

TERNA RETE ELETTRICA ADR by Terna Rete Elettrica Nazionale SPA

Terna SpA

TERNIUM ARGENTINA S A by TERNIUM ARGENTINA S A

Terna Energy SA

Terna Energy SA ADR

TRASMISSIONE ELECTR ORD by Terna Rete Elettrica Nazionale SPA

Ternoa

Press Releases

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Earnings

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Financing

Health Care

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Alumis

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Canopy Growth Corporation - Common Shares

Canopy Growth

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Cronos Group

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

LENZ Therapeutics

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Oculis Holding

Omeros

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Comments

Terns Pharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO